SCHEMBL4727588

SCHEMBL4727588

CCOC(=O)[C@@H](N)CSC(C)=O

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.39
LMNA P02545 2/20 0.39
HSD17B10 Q99714 1/20 0.39
ALOX15 P16050 1/20 0.38
CYP2D6 P10635 2/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
METAP2 P50579 4/20 0.36
METAP1 P53582 4/20 0.36
TSHR P16473 1/20 0.35
HTT P42858 1/20 0.35
CPB2 Q96IY4 1/20 0.35
NOD1 Q9Y239 1/20 0.34
GAA P10253 2/20 0.34
MGAM O43451 1/20 0.33
SI P14410 1/20 0.33
MGAM2 Q2M2H8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6233200 0.84 ALOX15 (0.38) ALDH1A1LMNAHSD17B10ALOX15CYP2D6
Hydrochloric Acid SCHEMBL11865499 0.83 ALDH1A1 (0.35) ALDH1A1LMNAHSD17B10ALOX15CYP2D6
SCHEMBL110807 0.81 ALOX15 (0.42) ALDH1A1LMNAHSD17B10ALOX15CYP2D6
SCHEMBL6304330 0.81 METAP2 (0.45) ALDH1A1LMNAHSD17B10ALOX15CYP2D6
SCHEMBL12707509 0.81 ALOX15 (0.42) ALDH1A1LMNAHSD17B10ALOX15CYP2D6
SCHEMBL11739657 0.81 ALOX15 (0.42) ALDH1A1LMNAHSD17B10ALOX15CYP2D6
SCHEMBL112490 0.81 ALOX15 (0.42) ALDH1A1LMNAHSD17B10ALOX15CYP2D6
SCHEMBL110806 0.81 ALOX15 (0.42) ALDH1A1LMNAHSD17B10ALOX15CYP2D6
SCHEMBL12438531 0.81 ALOX15 (0.42) ALDH1A1LMNAHSD17B10ALOX15CYP2D6
SCHEMBL12655937 0.81 ALOX15 (0.42) ALDH1A1LMNAHSD17B10ALOX15CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1231886-A4 TOPICAL SKIN COMPOSITION ACCESS BUSINESS GROUP INT LLC (US) 2005-10-12 EP claimed
CN-1424900-A Topical skin composition TONDAR COMMERCIAL GROUP INTERN (US) 2003-06-18 CN claimed
US-20030095959-A1 Topical skin composition ACCESS BUSINESS GROUP INTERNATIONAL LLC. 2003-05-22 US claimed
EP-1231886-A1 TOPICAL SKIN COMPOSITION Alticor Inc. (US) 2002-08-21 EP claimed
WO-2001037788-A1 TOPICAL SKIN COMPOSITION ALTICOR INC. (US) 2001-05-31 WO claimed
CN-102406607-B Tiopronin liposome injection HAINAN LINGKANG PHARMACEUTICAL 2012-11-21 CN disclosed
CN-102406607-A Tiopronin liposome injection HAINAN LINGKANG PHARMACEUTICAL 2012-04-11 CN disclosed
CN-101522266-A Topical skin compositions, their preparation, and their use ACCESS BUSINESS GROUP INT LLC (US) 2009-09-02 CN disclosed
US-20080124409-A1 Topical Skin Compositions, Their Preparation, and Their Use ACCESS BUSINESS GROUP INTERNATIONAL LLC 2008-05-29 US disclosed
US-20080081034-A1 Topical Skin Compositions, Their Preparation, and Their Use ACCESS BUSINESS GROUP INTERNATIONAL LLC 2008-04-03 US disclosed
US-20080081082-A1 Topical Skin Compositions, Their Preparation, and Their Use ACCESS BUSINES GROUP INTERNATIONAL LLC 2008-04-03 US disclosed
WO-2008016842-A1 TOPICAL SKIN COMPOSITIONS, THEIR PREPARATION, AND THEIR USE ACCESS BUSINESS GROUP INTERNATIONAL LLC (US) 2008-02-07 WO disclosed
WO-2008016838-A1 TOPICAL SKIN COMPOSITIONS, THEIR PREPARATION AND THEIR USE ACCESS BUSINESS GROUP INTERNATIONAL LLC (US) 2008-02-07 WO disclosed
US-20070003536-A1 Topical skin compositions, their preparation, and their use ACCESS BUSINESS GROUP INTERNATIONAL LLC 2007-01-04 US disclosed
EP-1231886-A4 TOPICAL SKIN COMPOSITION ACCESS BUSINESS GROUP INT LLC (US) 2005-10-12 EP disclosed
CN-1424900-A Topical skin composition TONDAR COMMERCIAL GROUP INTERN (US) 2003-06-18 CN disclosed
US-20030095959-A1 Topical skin composition ACCESS BUSINESS GROUP INTERNATIONAL LLC. 2003-05-22 US disclosed
EP-1231886-A1 TOPICAL SKIN COMPOSITION Alticor Inc. (US) 2002-08-21 EP disclosed
WO-2001037788-A1 TOPICAL SKIN COMPOSITION ALTICOR INC. (US) 2001-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080081034-A1 Topical Skin Compositions, Their Preparation, and Their Use COL14A1, MMP8, MMP1 ALDH1A1 1551/4885LMNA 200/4885HSD17B10 1453/4885
US-20080124409-A1 Topical Skin Compositions, Their Preparation, and Their Use COL14A1, MMP8, MMP1 ALDH1A1 1551/4885LMNA 200/4885HSD17B10 1453/4885
US-20030095959-A1 Topical skin composition CUTA, S100A4, KRT18 ALDH1A1 1227/4885LMNA 2296/4885HSD17B10 1033/4885
US-20070003536-A1 Topical skin compositions, their preparation, and their use COL14A1, MMP8, MMP1 ALDH1A1 1551/4885LMNA 200/4885HSD17B10 1453/4885
US-20080081082-A1 Topical Skin Compositions, Their Preparation, and Their Use COL14A1, MMP8, MMP1 ALDH1A1 1551/4885LMNA 200/4885HSD17B10 1453/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.